| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.73(B) |
| Last
Volume: |
3,013,019 |
Avg
Vol: |
2,434,266 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 17.5 |
| Insider 6 Months : 18.9 |
| Insider 3/6 Months : 36.8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
| Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
3 |
4 |
4 |
| Total Shares Sold |
80,531 |
241,700 |
593,372 |
1,012,962 |
| Total Sell Value |
$1,755,807 |
$5,376,989 |
$12,725,795 |
$20,083,859 |
| Total People Sold |
5 |
7 |
9 |
12 |
| Total Sell Transactions |
5 |
10 |
16 |
27 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Scangos George A |
Director |
– • – |
2019-07-01 |
4 |
AS |
$21.58 |
$863,200 |
D/D |
(40,000) |
1,168,031 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-19 |
4 |
OE |
$5.51 |
$95,896 |
D/D |
17,404 |
134,601 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-18 |
4 |
AS |
$20.67 |
$2,067,000 |
D/D |
(100,000) |
117,197 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-18 |
4 |
OE |
$1.70 |
$263,711 |
D/D |
100,000 |
217,197 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-17 |
4 |
AS |
$20.49 |
$2,410,307 |
D/D |
(117,404) |
117,197 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-17 |
4 |
OE |
$1.70 |
$538,259 |
D/D |
100,000 |
217,197 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-13 |
4 |
AS |
$20.03 |
$552,748 |
D/D |
(27,596) |
117,197 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2019-06-13 |
4 |
OE |
$5.56 |
$153,434 |
D/D |
27,596 |
144,793 |
|
- |
|
| Haley Patrick J. |
Sr. Vice President, Commercial |
• – – |
2019-06-10 |
4 |
AS |
$20.23 |
$20,230 |
D/D |
(1,000) |
88,453 |
|
- |
|
| Scangos George A |
Director |
– • – |
2019-06-04 |
4 |
AS |
$20.00 |
$300,000 |
D/D |
(15,000) |
1,208,031 |
|
- |
|
| Scangos George A |
Director |
– • – |
2019-06-03 |
4 |
AS |
$19.61 |
$490,250 |
D/D |
(25,000) |
1,223,031 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2019-05-29 |
4 |
OE |
$7.18 |
$104,763 |
D/D |
14,591 |
104,591 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
144,167 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
130,526 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
1,052,568 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
32,374 |
|
- |
|
| Poste George |
Director |
– • – |
2019-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
10,317 |
112,792 |
|
- |
|
| Scangos George A |
Director |
– • – |
2019-05-21 |
4 |
OE |
$4.57 |
$68,550 |
D/D |
15,000 |
1,248,031 |
|
- |
|
| Haley Patrick J. |
Sr. Vice President, Commercial |
• – – |
2019-05-10 |
4 |
AS |
$19.58 |
$19,580 |
D/D |
(1,000) |
89,453 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2019-05-08 |
4 |
AS |
$20.15 |
$846,300 |
D/D |
(42,000) |
90,000 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2019-05-08 |
4 |
OE |
$5.56 |
$233,520 |
D/D |
42,000 |
132,000 |
|
- |
|
| Willsey Lance |
Director |
– • – |
2019-05-08 |
4 |
S |
$20.36 |
$1,018,000 |
D/D |
(50,000) |
368,273 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2019-05-03 |
4 |
S |
$20.70 |
$750,603 |
D/D |
(36,261) |
112,362 |
|
- |
|
| Scangos George A |
Director |
– • – |
2019-05-02 |
4 |
AS |
$20.00 |
$300,000 |
D/D |
(15,000) |
1,233,031 |
|
- |
|
| Scangos George A |
Director |
– • – |
2019-05-01 |
4 |
AS |
$19.75 |
$493,750 |
D/D |
(25,000) |
1,248,031 |
|
- |
|
1428 Records found
|
|
Page 25 of 58 |
|
|
0.91 (4.38%) 
